"The field of radiation oncology is moving to treating in fewer fractions with higher doses," said Charlie Ma, Ph.D., Vice Chairman, Department of Radiation Oncology, Director, Radiation Physics at the Fox Chase Cancer Center in Philadelphia. "The addition of the MLC, combined with the CyberKnife's ability to deliver treatment from hundreds of angles while tracking and correcting for motion, will give us the flexibility to deliver the most accurate patient-specific and tailored dose distributions and allows a broader range of patients to benefit from highly efficient and effective treatments."
The CyberKnife M6 Series reduces treatment times with fewer Monitor Units (MUs) while delivering unrivaled dose distributions and further improving plan quality. This heightened efficiency allows users to schedule more patients per day, to not only ensure timely care to more cancer patients, but to also improve the return on their investment.
"Accuray developed the CyberKnife M6 Series to provide the radiation oncology community with a personalized, patient-focused treatment that delivers unmatched clinical capabilities and the ability to treat more patients with unprecedented levels of precision and efficiency," said Joshua H. Levine, president and chief executive officer of Accuray. "The development of the CyberKnife M6 Series addresses the needs of both physicians and patients, and reinforces Accuray's position as the leading technical innovator driving new clinical solutions in radiation oncology."
About AccurayAccuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 642 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expansion of the Company's global presence, clinical capabilities, treatment times, clinical efficiency, dose delivery, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on September 10, 2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements. SOURCE Accuray Incorporated